Rybrevant Faspro · head and neck cancer
OrigAMI-4 examined amivantamab in head and neck cancer. FDA based the new indication on a group of 102 previously treated patients.
View timeline (2)Biotechnology. Right now.
Clinical trial milestones and FDA decisions, linked by program and indication.
OrigAMI-4 examined amivantamab in head and neck cancer. FDA based the new indication on a group of 102 previously treated patients.
View timeline (2)AZUR-1 enrolled patients with previously untreated stage II or III locally advanced rectal cancer with MSI-high or mismatch-repair-deficient tumors.
View timeline (3)The DTX401 phase 3 study measured daily cornstarch use. FDA required further evidence of clinical benefit after accelerated approval.
View timeline (4)Study NCT02716246 was one of three records FDA cited in its review of Fayuvi for children with preserved neurodevelopmental function.
View timeline (2)